July 18, 2018
GlycoMantra received SBIR Phase 1 grant from the NCI (NIH)
GlycoMantra was awarded SBIR Phase 1 grant to investigate drug resistance in metastatic prostate cancer.
July 18, 2018
GlycoMantra received SBIR Phase 1 grant from the NCI (NIH)
GlycoMantra was awarded SBIR Phase 1 grant to investigate drug resistance in metastatic prostate cancer.